{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T11:12:45Z","timestamp":1791717165300,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejca.2025.116042","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:12:14Z","timestamp":1759540334000},"page":"116042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-5268","authenticated-orcid":false,"given":"Ilias","family":"Houda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-2414","authenticated-orcid":false,"given":"Dwayne","family":"Naves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-738X","authenticated-orcid":false,"given":"Ezgi B.","family":"Ulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-1826","authenticated-orcid":false,"given":"Birgit I.","family":"Lissenberg-Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole P.","family":"Barlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-2452","authenticated-orcid":false,"given":"Elisabeth A.","family":"Kastelijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Bouhaddou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-8372","authenticated-orcid":false,"given":"Chris","family":"Dickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Radonic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Famke L.","family":"Schneiders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-2204","authenticated-orcid":false,"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-7047","authenticated-orcid":false,"given":"Ronald A.M.","family":"Damhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-608X","authenticated-orcid":false,"given":"Idris","family":"Bahce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2025.116042_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","article-title":"What's new in SCLC? A review","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.ejca.2025.116042_bib2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2025.116042_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ejca.2025.116042_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2730)","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116042_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO-24-02245","article-title":"Systemic therapy for small cell lung cancer: ASCO guideline rapid recommendation update","volume":"43","author":"Kalemkerian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116042_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(00)00127-6","article-title":"A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis","volume":"30","author":"Mascaux","year":"2000","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2025.116042_bib7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/83.12.855","article-title":"Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer","volume":"83","author":"Fukuoka","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"10212","key":"10.1016\/j.ejca.2025.116042_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ejca.2025.116042_bib9","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line treatment of PD-L1\u2013Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.116042_bib10","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/curroncol28040243","article-title":"Patterns of relapse in small cell lung cancer: competing risks of thoracic versus CNS relapse","volume":"28","author":"Ellis","year":"2021","journal-title":"Curr Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2025.116042_bib11","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-Dose Once-Daily thoracic radiotherapy in Limited-Stage Small-Cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116042_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000001066","article-title":"Hyperfractionated accelerated radiotherapy versus stereotactic body radiotherapy in the treatment of Limited-Stage small cell lung cancer: a Matched-Pair analysis","volume":"47","author":"Yang","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116042_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116042_bib14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ijrobp.2024.02.063","article-title":"Long-Term outcomes after concurrent Once- or Twice-Daily chemoradiation in Limited-Stage small cell lung cancer: a brief report from the CONVERT trial","volume":"119","author":"Walls","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.ejca.2025.116042_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/theoncologist.2009-0026","article-title":"New advances in the second-line treatment of small cell lung cancer","volume":"14","author":"Hurwitz","year":"2009","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ejca.2025.116042_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.116042_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2022.11.014","article-title":"Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification","volume":"175","author":"Caliman","year":"2023","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2025.116042_bib18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in Limited-Stage Small-Cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116042_bib19","unstructured":"U.S. Food & Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer; 2024; Accessed January 18, 2025."},{"key":"10.1016\/j.ejca.2025.116042_bib20","unstructured":"AstraZeneca. \u3008https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/imfinzi-approved-in-eu-for-limited-stage-sclc.html\u3009; Accessed May 7, 2025."},{"issue":"35","key":"10.1016\/j.ejca.2025.116042_bib21","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic therapy for Small-Cell lung cancer: ASCO-Ontario health (Cancer Care Ontario) guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2025.116042_bib22","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116042_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/COC.0b013e31828aab2a","article-title":"Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide","volume":"38","author":"Karam","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116042_bib24","unstructured":"https:\/\/www.rijksoverheid.nl\/onderwerpen\/coronavirus-tijdlijn\/2020; Accessed November 9, 2024."},{"key":"10.1016\/j.ejca.2025.116042_bib25","unstructured":"https:\/\/www.rijksoverheid.nl\/onderwerpen\/coronavirus-tijdlijn\/2021; Accessed November 9, 2024."},{"key":"10.1016\/j.ejca.2025.116042_bib26","unstructured":"https:\/\/www.rijksoverheid.nl\/onderwerpen\/coronavirus-tijdlijn\/2022; Accessed November 9, 2024."},{"key":"10.1016\/j.ejca.2025.116042_bib27","article-title":"Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer","volume":"35","author":"Sama","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.ejca.2025.116042_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.37699","article-title":"Comparison of carboplatin with cisplatin in small cell lung cancer in US veterans","volume":"5","author":"Azar","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925006288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925006288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:51:41Z","timestamp":1761947501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925006288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"alternative-id":["S0959804925006288"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116042","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116042"}}